TORONTO, March 25, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a life sciences company focused on the research and development of therapeutics for rare disorders and infectious diseases, is pleased to announce that the Company has retained Pharm-Olam, LLC, with proven clinical experience in infectious diseases completing over 100 clinical studies in approximately 19,000 patients at over 2,000 clinical sites, to serve as the Company’s Contract Research Organization (“CRO”) to advance the future clinical study for Bucillamine in the treatment of infectious diseases, including the coronavirus disease (“COVID-19”). In addition, Revive has added Dr. Kelly McKee, Jr., MD, MPH as Chief Scientific Officer consultant and Dr. Onesmo Mpanju, PhD as Regulatory Affairs consultant to the Company’s clinical development team.
Pharm-Olam, a global midsized CRO, today announced that the company’s board of directors has elected Robert Davie, Ph.D., as its new chief executive officer. Pharm-Olam provides full-service clinical development solutions for oncology-hematology, infectious disease, vaccines, and rare diseases. Davie succeeds David Grange who has served as Pharm-Olam’s CEO since March 2017. Grange will remain a director and vice chairman of the company’s board and will continue to support the organization and its work in U.S. government-funded research, which is an expanding area of Pharm-Olam’s business. “Rob Davie is a respected leader who has worked within the CRO industry for over 25 years. We look forward to his leadership and knowledge supporting the continued growth of Pharm-Olam,” said Zev Munk. M.D., founder and chairman of the board. “We also extend our sincere thanks to David Grange for his leadership over the past two-and-a-half years having transformed Pharm-Olam’s therapeutic focus while achieving record sales for 2018.”
As a thank you for subscribing, you'll receive a free copy of our GDPR Controller & Processor Checklist
Houston, June 10th, 2019 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for oncology-hematology, infectious diseases and vaccines and rare diseases, will be sharing key strategies for pharmaceutical companies needing to transition studies to a different CRO in a free webinar on June 18.
Houston, April 3rd, 2019 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for oncology, infectious diseases and vaccines, and rare and orphan diseases, has been named a winner in Life Science Leader magazine’s 2019 CRO Leadership Awards. Pharm-Olam was rated highly by small pharma survey respondents, as well as all survey respondents combined, for delivering excellent clinical research services in Compatibility, Quality, and Reliability core award categories.
Houston, March 6, 2019 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for oncology-hematology, infectious diseases and vaccines, and rare diseases, is marking its 25th anniversary with several announcements. These include an update to its rare disease service tier, progress on its transition to the Medidata Cloud platform, and ongoing global expansion. With record sales in 2018, these changes position Pharm-Olam for continued growth into 2019.
Houston, Feb. 5, 2019 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for rare and orphan diseases along with oncology, infectious diseases, and vaccines, is now enrolling patients in the U.S. and Europe into a pivotal Phase III study within the treatment of short bowel syndrome (SBS).
Houston, Oct. 30, 2018 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for oncology, infectious diseases and vaccines, and rare and orphan diseases, extends its congratulations to Ablynx, a Sanofi company, for its launch of Cablivi® (caplacizumab) in the German market for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). Pharm-Olam is proud to have contributed to the execution and completion of its pivotal Phase III study.
CRO accelerates the delivery of life-changing therapies with a single view of data for all clinical trial stakeholders